DZ
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

Lithium cocrystal

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác
Lithium cocrystal
Lithium salicylate (top) and L-proline (bottom)
Combination of
Lithium salicylateLithium salt
L-ProlineAmino acid
Clinical data
Trade namesAL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO
Routes of
administration		oral
Drug classMood stabilizer

Lithium cocrystal (AL-001, Lithium salicylate/L-proline cocrystal, LiProSal, LISPRO) is a form of lithium that combines lithium salicylate and the amino acid L-proline.[1][2] The ionic cocrystal (ICC) form combines the lithium salt with an organic anion.[3][4] This formulation allows more of the compound to cross the blood brain barrier and into the central nervous system.[5] The lithium salicylate/L-proline cocrystal allows approximately 20% lower blood serum levels versus lithium carbonate, and thus fewer attendant side effects.[6][7] The compound is in phase 2 clinical trials for Alzheimer's disease, bipolar disorder, major depressive disorder and PTSD.[8] Lithium cocrystal was created in 2004 at the University of South Florida.[6] It is under development by Alzamend Neuro with the designation AL-001.[8][9][10]

See also

[edit]

References

[edit]
  1. ^ PubChem. "Lithium Salicylate". pubchem.ncbi.nlm.nih.gov. Retrieved 2026-01-10.
  2. ^ Li, Yanping; Chen, Hua; Lai, Jimin; Huang, Xinlan; Leng, Guangjian; Zhang, Haoran; Lin, Zehong; Liu, Jitao; Xiao, Ercheng; Xu, Wei (2024-11-05). "Novel lithium ionic cocrystals with benzoic acid derivatives and L-proline: Synthesis, X-ray structures, IR spectrums, DSC analysis, and water solubility". Journal of Molecular Structure. 1315: 138795. doi:10.1016/j.molstruc.2024.138795. ISSN 0022-2860.{{cite journal}}: CS1 maint: article number as page number (link)
  3. ^ Smith, Adam J.; Kim, Seol-Hee; Duggirala, Naga K.; Jin, Jingji; Wojtas, Lukasz; Ehrhart, Jared; Giunta, Brian; Tan, Jun; Zaworotko, Michael J.; Shytle, R. Douglas (2013-12-02). "Improving lithium therapeutics by crystal engineering of novel ionic cocrystals". Molecular Pharmaceutics. 10 (12): 4728–4738. doi:10.1021/mp400571a. ISSN 1543-8392. PMC 3850245. PMID 24191685.
  4. ^ Sanii, Rana; Andaloussi, Yassin H.; Patyk-Kaźmierczak, Ewa; Zaworotko, Michael J. (2022-06-01). "Polymorphism in Ionic Cocrystals Comprising Lithium Salts and l-Proline". Crystal Growth & Design. 22 (6): 3786–3794. doi:10.1021/acs.cgd.2c00172. ISSN 1528-7483. PMC 9490868. PMID 36160301.
  5. ^ Habib, Ahsan; Shytle, R. Douglas; Sawmiller, Darrell; Koilraj, Selina; Munna, Sadia Afrin; Rongo, David; Hou, Huayan; Borlongan, Cesario V.; Currier, Glenn; Tan, Jun (1 September 2019). "Comparing the effect of the novel ionic cocrystal of lithium salicylate proline (LISPRO) with lithium carbonate and lithium salicylate on memory and behavior in female APPswe/PS1dE9 Alzheimer's mice". Journal of Neuroscience Research. 97 (9): 1066–1080. doi:10.1002/jnr.24438. ISSN 1097-4547. PMC 6625860. PMID 31102295.
  6. ^ a b "Lithium: 12 Updates from 2023 | CARLAT PUBLISHING". www.thecarlatreport.com. Retrieved 2026-01-09.
  7. ^ Lobo, Andrea (2024-09-04). "New partners for Phase 2 trial of next-gen lithium therapy AL001". www.alzheimersnewstoday.com. Retrieved 2026-01-13.
  8. ^ a b "Lithium cocrystal - Alzamend Neuro - AdisInsight". adisinsight.springer.com. Retrieved 2026-01-13.
  9. ^ Cummings, Jeffrey L.; Osse, Amanda M. Leisgang; Kinney, Jefferson W. (1 Oct 2023). "Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification". Drugs. 83 (15): 1387–1408. doi:10.1007/s40265-023-01938-w. ISSN 1179-1950. PMC 10582128. PMID 37728864.
  10. ^ "Next-generation lithium treatment for bipolar disorder to be studied". www.healio.com. Retrieved 2026-01-13.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.